Document ID: chunk:federal_register_of_legislation:F2025C00158:clause:4_1:p47
Version: federal_register_of_legislation:F2025C00158
Segment Type: clause
Provision Reference: sch 4 cl 1 (pt 47/191)
Character Range: 10009075–10021672

suitable PBS-listed drugs.
C5889               P5889          CN5889           Electrolyte replacement, oral                                                                                                                                              For treatment of a patient identifying as Aboriginal or Torres Strait Islander

C5893               P5893          CN5893           Amoxicillin with clavulanic acid                                                                                                                                           Infection where resistance to amoxicillin is suspected

C5894               P5894          CN5894           Amoxicillin with clavulanic acid                                                                                                                                           Infections where resistance to amoxicillin is proven

C5901               P5901          CN5901           Octreotide                                                                                                                                                                 Functional carcinoid tumour                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Compliance with Authority Required procedures - Streamlined Authority Code 5901
                                                                                                                                                                                                                               Patient must have achieved symptom control on octreotide immediate release injections; AND
                                                                                                                                                                                                                               The treatment must cease if there is failure to produce a clinically significant reduction in the frequency and severity of symptoms after 3 months therapy at a dose of 30 mg every 28 days and having allowed adequate rescue therapy with octreotide immediate release injections.
                                                                                                                                                                                                                               Dosage and tolerance to the drug should be assessed regularly and the dosage should be titrated slowly downwards to determine the minimum effective dose.
C5905               P5905          CN5905           Cefotaxime                                                                                                                                                                 Infection where positive bacteriological evidence confirms that this antibiotic is an appropriate therapeutic agent

C5906               P5906          CN5906           Octreotide                                                                                                                                                                 Vasoactive intestinal peptide secreting tumour (VIPoma)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  Compliance with Authority Required procedures - Streamlined Authority Code 5906
                                                                                                                                                                                                                               Patient must have achieved symptom control on octreotide immediate release injections; AND
                                                                                                                                                                                                                               The treatment must cease if there is failure to produce a clinically significant reduction in the frequency and severity of symptoms after 3 months therapy at a dose of 30 mg every 28 days and having allowed adequate rescue therapy with octreotide immediate release injections.
                                                                                                                                                                                                                               Dosage and tolerance to the drug should be assessed regularly and the dosage should be titrated slowly downwards to determine the minimum effective dose.
C5907               P5907          CN5907           Risperidone                                                                                                                                                                Acute mania                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Compliance with Authority Required procedures - Streamlined Authority Code 5907
                                                                                                                                                                                                                               The condition must be associated with bipolar I disorder; AND
                                                                                                                                                                                                                               The treatment must be as adjunctive therapy to mood stabilisers; AND
                                                                                                                                                                                                                               The treatment must be limited to up to 6 months per episode.
C5912               P5912          CN5912           Risperidone                                                                                                                                                                Bipolar I disorder                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Compliance with Authority Required procedures - Streamlined Authority Code 5912
                                                                                                                                                                                                                               The condition must be refractory to treatment; AND
                                                                                                                                                                                                                               The treatment must be in combination with lithium or sodium valproate; AND
                                                                                                                                                                                                                               The treatment must be maintenance therapy.
C5914               P5914          CN5914           Thalidomide                                                                                                                                                                Multiple myeloma                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Compliance with Authority Required procedures - Streamlined Authority Code 5914

C5936               P5936          CN5936           Aciclovir                                                                                                                                                                  Initial moderate to severe genital herpes                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                Compliance with Authority Required procedures - Streamlined Authority Code 5936
                                                                                                                                                                                                                               Microbiological confirmation of diagnosis [viral culture, antigen detection or nucleic acid amplification by polymerase chain reaction (PCR)] is desirable but need not delay treatment.
C5937               P5937          CN5937           Famciclovir                                                                                                                                                                Recurrent moderate to severe genital herpes                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Compliance with Authority Required procedures - Streamlined Authority Code 5937
                                                                                                                                                                                                                               Episodic treatment
                                                                                                                                                                                                                               Microbiological confirmation of diagnosis [viral culture, antigen detection or nucleic